№ lp_2_3_37340
File format: docx
Character count: 3001
File size: 413 KB
Conference schedule and descriptions including keynote speeches, café sessions, and discussions illustrate community housing associations’ engagement with local populations to address poverty and promote social development.
Date:
Friday 16th June
Location:
Cadder Community Centre, Glasgow, Scotland
Event Type:
One-day members conference
Organizer:
Glasgow and West of Scotland Forum (GWSF)
Participants:
CCHAs, community members, policy advisors
Speakers:
Peter Howden, Colleen Rowan, David Cowan, Francis Stuart, Maureen Cope, Sandy Campbell, Fraser Stewart, David Bookbinder
Sessions:
Plenary talks, café sessions, networking
Topics:
Poverty reduction, community development, youth employment, succession planning
Booking Contact:
Eleanor McCormack
Email:
[email protected]
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
Not specified
Region / City:
Moses Lake
Topic:
Youth football rules and regulations
Document Type:
Official rules
Organization / Institution:
Moses Lake Grid Kids Football
Author:
Not specified
Target Audience:
Youth players, coaches, and parents involved in Moses Lake Grid Kids Football
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2021
Region / City:
North Carolina
Theme:
Tackle Football, Flag Football
Document Type:
Rules of Play
Organization:
AAU (Amateur Athletic Union)
Author:
Not specified
Target Audience:
Coaches, Athletes, Team Administrators
Period of Validity:
2021 Season
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2020
Region / City:
London
Theme:
Climate Change, Green Finance
Document Type:
Report
Organization / Institution:
London Sustainable Development Commission (LSDC)
Author:
Dr. Ashok Sinha
Target Audience:
Government Officials, Environmental Policy Makers, Investors
Effective Period:
2020-2050
Approval Date:
2020
Revision Date:
N/A
Context:
A report on the need for significant investment restructuring in London to achieve its climate goals, focusing on the establishment of a new financial facility to facilitate the city’s transition to a low-carbon economy.
Year:
2025
Season:
Fall 2025
Region / City:
Springville
Program Name:
Springville Youth Football
Organizing Body:
Youth Sports Foundation
Affiliation:
USA Football
Type of Document:
Public registration announcement
Sport:
Youth tackle football
Eligible Grades:
5th and 6th grade
Age Requirements:
Must turn at least 10 during 5th grade year and not turn 13 before September 15 of 6th grade year
Program Start Date:
Week of August 11, 2025
First Game Date:
September 7, 2025
Number of Games:
Six-game schedule
Game Days:
Sundays
Registration Method:
Online registration via Youth Sports Foundation website
Registration Fee:
$180.00 plus $5.00 processing fee
Optional Equipment:
Hard-cup chin strap ($25.00)
Equipment Fitting Date:
Tuesday, March 11
Equipment Fitting Time:
4:00–7:00 p.m.
Equipment Fitting Location:
Springville High School
Online Registration Deadline:
March 8, 2025
Late Fee Policy:
$50.00 after June 27, 2025
Refund Policy:
Refunds (less $35.00) available until 3:30 p.m. Friday, August 15, 2025; no refunds after August 15
Team Capacity:
Limited team numbers
Contact Person:
Joe Martin
Coordinator Phone:
(319) 310-6662
YSF Office Phone:
563-288-2541
Website:
www.youthsportsfoundation.org
Note:
Year
Subject:
Lead restrictions in fishing tackle
Document Type:
Regulation Annex
Organization:
European Union
Author:
European Commission
Target Audience:
Manufacturers, retailers, fishing industry
Effective Period:
From the specified dates after the EIF of this Regulation
Year:
2013
Region / city:
Ekurhuleni
Topic:
HIV/AIDS, Higher Education
Document Type:
Media Release
Organization:
Higher Education HIV/AIDS Programme (HEAIDS)
Author:
Jo-Anne Collinge
Target Audience:
Academic staff, public universities, Further Education and Training colleges
Action Period:
2013
Approval Date:
29 August 2013
Modification Date:
Not mentioned
Year:
2014
Team:
Denver Broncos
Player:
Kevin Vickerson
Position:
Defensive Tackle
Event:
Preseason Training Camp
Date of Statements:
August 26, 2014
Topic:
Player Comments on Preseason Competition and Injury Recovery
Source Type:
Sports Interview
League:
NFL
Year:
2025
Region / City:
Davenport, IA
Subject:
Youth sports, tackle football
Document Type:
Registration announcement
Organization:
Youth Sports Foundation
Target Audience:
Students entering grades 3-6 and their parents
Program Dates:
August 11, 2025 – six-game schedule starting September 7, 2025
Registration Fee:
$180 + $5 processing fee
Optional Equipment:
Hard-cup chin strap $25
Equipment Fitting Dates:
May 13-14, 2025, 5:30–6:30 p.m., North High School Gym Lobby Entrance
Late Fee Policy:
$50 after June 27, 2025
Refund Policy:
Up to August 15, 2025, less $35 processing fee
Contact:
TJ Sheedy, 563-349-9612, [email protected]
Website:
www.youthsportsfoundation.org
Coaching:
Certified coaches, USA Football affiliation
Year:
2022
Region / City:
Australia
Topic:
Medical treatment approval and submission for pembrolizumab and lenvatinib
Document type:
Submission for drug listing
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC), Therapeutic Goods Administration (TGA)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Medical professionals, health regulators
Period of validity:
2022 onward
Approval date:
August 10, 2021
Amendment date:
Not specified
Year:
2023
Region / City:
Australia
Theme:
Oncology, Pharmaceutical
Document Type:
Submission
Organization / Institution:
Merck Sharp & Dohme (Australia) Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, policymakers
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Australia
Subject:
Oncology / Colorectal Cancer Treatment
Document Type:
Medical submission
Agency / Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Not specified
Target Audience:
Medical practitioners
Effective Period:
Ongoing
Approval Date:
Not provided
Date of Revision:
Not provided
Year:
2024
Region / City:
Australia
Topic:
Oncology / Cancer Treatment
Document Type:
Pharmaceutical Submission
Organization:
Merck Sharp & Dohme
Author:
Merck Sharp & Dohme
Target Audience:
Healthcare professionals, regulatory bodies, pharmaceutical industry
Effective Period:
From September 2024
Approval Date:
Pending
Date of Changes:
September 2024
Context:
A submission by Merck Sharp & Dohme to request a multi-indication listing for pembrolizumab to treat advanced or metastatic cancers under the Pharmaceutical Benefits Scheme in Australia.
Year:
2022
Region / City:
Australia
Theme:
Oncology, Pharmacology
Document Type:
Addendum
Organ / Institution:
Merck Sharp & Dohme (Australia) Pty Ltd
Author:
Not specified
Target Audience:
Healthcare professionals, regulatory bodies
Period of Validity:
Indication approved on February 7, 2022
Approval Date:
07 February 2022
Change Date:
Not specified
Year:
2022
Region / city:
Australia
Topic:
Early-stage triple negative breast cancer treatment
Document type:
Pharmaceutical submission
Organization / institution:
Merck Sharp & Dohme (Australia) Pty Ltd
Author:
Not specified
Target audience:
Medical professionals, healthcare providers
Effective period:
From September 2022
Approval date:
2 September 2022
Modification date:
Not specified
Registration status:
Approved by TGA
Background:
Pembrolizumab was approved by the TGA for the treatment of early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and as monotherapy post-surgery.
Condition:
Triple negative breast cancer
Indication:
Early stage triple negative breast cancer
Restriction:
Section 100 (Efficient funding of chemotherapy), Authority Required – Streamlined
Treatment initiation criteria:
Hormone receptor negative, HER2 negative, preparing for surgery, ECOG status 1 or less, treatment combined with chemotherapy, no previous treatment, not exceeding 24 weeks of therapy
Continuation criteria:
Must have undergone surgery, ECOG status 1 or less, monotherapy for adjuvant phase, no more than 27 weeks of therapy
Grandfathering criteria:
Must have previously received non-PBS subsidised treatment
Price:
$7,881.87 private, $7,733.78 public for neoadjuvant; private and public prices for adjuvant not specified
Number of doses:
7 for neoadjuvant, 8 for adjuvant
Source:
Table 1.1-1, pp12-14
Context description:
A pharmaceutical submission for the approval of pembrolizumab as a treatment for early-stage triple-negative breast cancer, including neoadjuvant and adjuvant therapy details and pricing for PBS listing.
Year:
2021
Region / City:
Australia
Topic:
Pneumococcal vaccine submission
Document type:
Submission for listing on the National Immunisation Program
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Health professionals, regulatory bodies, policy makers
Period of validity:
Ongoing
Approval date:
16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes:
Not specified
Context:
A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
Year:
2017
Region / city:
Australia
Theme:
Oncology, Immunotherapy
Document type:
Pharmaceutical Submission
Organization / Institution:
Merck Sharp & Dohme (Australia) Pty Ltd
Author:
Merck Sharp & Dohme
Target audience:
Healthcare professionals, medical practitioners
Effective period:
Ongoing
Approval date:
March 2017
Changes date:
Not specified
Context:
A pharmaceutical submission for the listing of pembrolizumab for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients, detailing proposed PBS listings, treatment phases, and clinical criteria.
Year:
2023
Region / city:
Australia
Topic:
Pneumococcal vaccination
Document type:
Submission
Agency / organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Healthcare professionals involved in immunization
Period of validity:
Not specified
Approval date:
Expected by 30 April 2023
Date of changes:
9 February 2023
Year:
2022
Region / City:
North Carolina
Topic:
Occupational Health and Safety
Document Type:
Government Letter
Organization / Institution:
North Carolina Department of Labor
Author:
Kevin O’Barr
Target Audience:
SHARP Employers in North Carolina
Period of Action:
2022
Approval Date:
January 5, 2022
Modification Date:
N/A
Year:
2023
Region / City:
North Carolina
Theme:
Housing Finance, Supportive Housing
Document Type:
Application Form
Organization:
North Carolina Housing Finance Agency (NCHFA)
Author:
NCHFA
Target Audience:
Housing developers, nonprofit organizations, local governments
Period of Validity:
Until July 21, 2023
Approval Date:
July 21, 2023
Date of Modifications:
N/A
Year:
N/A
Region / City:
N/A
Theme:
History, English Monarchs
Document Type:
Exercise
Author:
N/A
Target Audience:
Students of English, History
Validity Period:
N/A
Approval Date:
N/A
Date of Changes:
N/A